****imagin_logo_v2.png

**Imagin Medical**

**Announces Private Placement**

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

***Vancouver, B.C. and Boston, MA,***April 3, 2018 – Imagin Medical, Inc. (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today the offering of a non-brokered private placement to raise up to $3,500,000 through the distribution of units (“Units”) at $0.22 per Unit.

Each Unit will consist of one common share and one common share purchase warrant, each warrant entitling the holder to acquire one additional common share at $0.38 for 24 months.

Finder’s fees may be paid in accordance with Canadian Securities Exchange policies. Closing of the placement will be subject to making applicable filings with the CSE.

The Company anticipates the offering will close on or about April 11, 2018.

Finder’s fees may be paid in accordance with Canadian Securities Exchange policies.

Closing of the placement will be subject to making applicable filings with the CSE.

Proceeds from the placement will be used for general working capital purposes, including advancing the development of imaging solutions for the early detection of cancer.

**About Imagin Medical**

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at [www.imaginmedical.com](http://www.imaginmedical.com/)

**For further information, contact:**

Jim Hutchens, President & CEO

Telephone: 617-571-6006

Email: jhutchens (AT) imaginmedical.com

­­­­­­­­­­­­­­­­­­­­­­­­

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.*

|  |  |
| --- | --- |
| U.S. HQ:  69 Longwood Avenue    Hyannis Port, MA 02647  USA  617-571-6006 | CA HQ:  890 West Pender Street, Suite 600  Vancouver, British Columbia  Canada V6C 1J9  778-998-5000; 604-687-1327 (fax) |

NR-2018-IME-#15